Literature DB >> 20940537

No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons.

Jerome LeGoff, Clare Tanton, Constance Delaugerre, Helen A Weiss, John Changalucha, David A Ross, Kokugonza Mugeye, Laurent Belec, Richard J Hayes, Deborah Watson-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20940537     DOI： 10.1097/QAD.0b013e32833e5176

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

Review 2.  Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.

Authors:  Ruanne V Barnabas; Connie Celum
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

3.  Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.

Authors:  Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis
Journal:  Clin Infect Dis       Date:  2015-03-03       Impact factor: 9.079

4.  Time to refocus on HSV interventions for HIV prevention?

Authors:  Clare Tanton; Laith J Abu-Raddad; Helen A Weiss
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.